MX2023015016A - Pirrolo[2,3-d]pirimidinas sustituidas, su preparacion y su aplicacion terapeutica. - Google Patents

Pirrolo[2,3-d]pirimidinas sustituidas, su preparacion y su aplicacion terapeutica.

Info

Publication number
MX2023015016A
MX2023015016A MX2023015016A MX2023015016A MX2023015016A MX 2023015016 A MX2023015016 A MX 2023015016A MX 2023015016 A MX2023015016 A MX 2023015016A MX 2023015016 A MX2023015016 A MX 2023015016A MX 2023015016 A MX2023015016 A MX 2023015016A
Authority
MX
Mexico
Prior art keywords
pyrimidines
preparation
therapeutic application
compounds
substituted pyrrolo
Prior art date
Application number
MX2023015016A
Other languages
English (en)
Spanish (es)
Inventor
Stéphanie Deprets
Corinne Terrier
Laurent Dubois
Patrick Bernardelli
Marc Bianciotto
Frédéric PETIT
John Macor
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21315095.6A external-priority patent/EP4105218A1/en
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2023015016A publication Critical patent/MX2023015016A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
MX2023015016A 2021-06-15 2022-06-14 Pirrolo[2,3-d]pirimidinas sustituidas, su preparacion y su aplicacion terapeutica. MX2023015016A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21315095.6A EP4105218A1 (en) 2021-06-15 2021-06-15 Substituted pyrrolo[2,3-d] pyrimidines, their preparation and their therapeutic application
EP22315117 2022-06-02
PCT/EP2022/066231 WO2022263472A1 (en) 2021-06-15 2022-06-14 Substituted pyrrolo[2,3-d]pyrimidines, their preparation and their therapeutic application

Publications (1)

Publication Number Publication Date
MX2023015016A true MX2023015016A (es) 2024-05-31

Family

ID=82214141

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023015016A MX2023015016A (es) 2021-06-15 2022-06-14 Pirrolo[2,3-d]pirimidinas sustituidas, su preparacion y su aplicacion terapeutica.

Country Status (11)

Country Link
US (1) US20240383901A1 (cg-RX-API-DMAC7.html)
EP (1) EP4355748B1 (cg-RX-API-DMAC7.html)
JP (1) JP7886355B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240021910A (cg-RX-API-DMAC7.html)
AU (1) AU2022294022A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023025042A2 (cg-RX-API-DMAC7.html)
CA (1) CA3223786A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024000083A2 (cg-RX-API-DMAC7.html)
IL (1) IL309195A (cg-RX-API-DMAC7.html)
MX (1) MX2023015016A (cg-RX-API-DMAC7.html)
WO (1) WO2022263472A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL330303A (en) * 2023-12-27 2026-08-01 Sanofi Modified pyrrolo[2,3-d]pyrimidins, their preparation and therapeutic applications
KR20250163526A (ko) 2024-05-14 2025-11-21 김성우 음전하 증폭장치가 장착된 어싱용 발판

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
FR2988722B1 (fr) 2012-04-03 2014-05-09 Sanofi Sa Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques
CN106146515B (zh) 2015-04-17 2020-09-04 常州隆赛医药科技有限公司 新型激酶抑制剂的制备及应用
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
CN108934162A (zh) 2015-12-16 2018-12-04 南方研究所 吡咯并嘧啶化合物、作为激酶lrrk2抑制剂的用途及其制备方法
EP3587422A4 (en) 2017-02-22 2020-05-06 Daegu-Gyeongbuk Medical Innovation Foundation PYRROLOPYRIMIDINE DERIVATIVE COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION WITH THIS COMPOUND AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE
EP3873471B1 (en) 2018-10-31 2025-12-31 Merck Sharp & Dohme LLC N-HETEROARYL INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS: PHARMACEUTICAL COMPOSITIONS AND THEIR USES
EP3915985A4 (en) 2019-01-18 2022-09-28 Voronoi Co., Ltd. PYRROLOPYRIDE DERIVATIVE AND USE THEREOF FOR THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASES

Also Published As

Publication number Publication date
JP2024525150A (ja) 2024-07-10
IL309195A (en) 2024-02-01
JP7886355B2 (ja) 2026-07-07
WO2022263472A1 (en) 2022-12-22
KR20240021910A (ko) 2024-02-19
CO2024000083A2 (es) 2024-04-08
BR112023025042A2 (pt) 2024-02-27
US20240383901A1 (en) 2024-11-21
EP4355748A1 (en) 2024-04-24
AU2022294022A1 (en) 2024-02-01
EP4355748C0 (en) 2026-05-13
CA3223786A1 (en) 2022-12-22
EP4355748B1 (en) 2026-05-13

Similar Documents

Publication Publication Date Title
MX2024007058A (es) Derivados de 5,6,7,8-tetrahidro-2,6-naftiridina como terapeuticos contra el cancer.
PH12021553238A1 (en) Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors
NZ766835A (en) Pharmaceutical compounds
WO2024215862A3 (en) Heterocyclic compounds as nras inhibitors
MY180666A (en) Substituted pyrazolo [3,4-b] pyridines as medicaments
MX2010003927A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b.
NZ596301A (en) Novel 7-deazapurine nucleosides for therapeutic uses
PH12013501594A1 (en) Substituted indazole derivatives active as kinase inhibitors
BRPI0411868B8 (pt) derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase
HRP20050967B8 (hr) Derivati pirazolo-kinazolina, postupak njihovog dobivanja i njihova uporaba kao inhibitora kinaze
PT1678166E (pt) Inibidores de proteína-quinase
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
MX2009006401A (es) Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
MX2009003874A (es) Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
WO2008046087A3 (en) Spiro compounds and their uses as therapeutic agents
BRPI0409427A (pt) composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo
SG11201806438UA (en) Fused Pyrazole Derivatives, Preparation Method Thereof, And Use Thereof In Treatment Of Cancers, Inflammation And Immune Diseases
WO2008070313A3 (en) 3-(dihydro-1h-pyrazolo [4,3-d] pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
PH12021552533A1 (en) Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease
WO2020247298A3 (en) 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
MX2019010756A (es) Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2).
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
MY195262A (en) Pharmacologically Active Alicyclic-Substituted Pyrazolo[1,5-A]Pyrimidine Derivatives
MX418886B (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo